Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
7 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide - 27 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- 3Step by step instructions to Analyze Senior Insurance Contracts Really.
- 4Vote In favor of Your Favored Sort Of Bevarage
- 5'Women on the floor, riddled with bullets': Ex-hostage Rom Braslavski recounts 'horrors' of Oct. 7
- Artemis 2 moon rocket gets 'America 250' paint job | Space photo of the day for Dec. 23, 2025
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- The 10 Most Compelling Forerunners in Innovation
- A top Marine shares his secrets to keeping fit at 50
- Medical team successfully delivers baby and removes massive tumor
- ACA subsidies latest: Making sense of what's happening with health care after Republicans revolt, forcing a vote on funding extension
- Vote In favor of Your Favored Occasion Arranging Administration
- High-Suggested Broilers For Your Homes
- Instructions to Expand Your Advantages from an Open Record Reward
